BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG

Their core work

BRAIN AG is a German industrial biotechnology company that discovers, engineers, and optimizes enzymes and proteins for commercial applications — particularly in consumer goods, food, and green chemistry. Their core work sits at the intersection of protein evolution and industrial bioprocessing: they take enzymes found in nature or designed computationally and make them fast, stable, and cost-effective enough for manufacturing scale. In H2020, they contributed as a specialist partner bringing wet-lab enzyme screening, metagenomics-based discovery, and machine-learning-guided protein engineering to large European consortia. As a private company (not a university), they operate with a commercial lens — their science is oriented toward products, not just publications.

What they specialise in

How they've shifted over time

In their earlier H2020 engagement (ES-Cat, 2017–2021), BRAIN AG contributed to an MSCA doctoral training network centered on protein evolution and biocatalysis — a foundational, academically-oriented role with no specific technology keywords recorded against their contribution. By the time RADICALZ began (2021–2025), the focus had shifted decisively toward applied, technology-dense enzyme discovery: microfluidics, metagenomics, protein engineering, machine learning, and bioprocess sustainability all appear together. This progression suggests BRAIN AG has moved from classical directed evolution toward a fully integrated, data-accelerated discovery platform where computational prediction and high-throughput experimental validation work in tandem. The sustainability framing in RADICALZ also signals alignment with green chemistry and circular economy demands from the consumer goods sector.

BRAIN AG is heading toward fully integrated, data-driven enzyme platforms — combining metagenomics sourcing, microfluidics screening, and machine learning prediction — with increasing emphasis on sustainability credentials that align with consumer goods and food industry procurement requirements.

How they like to work

BRAIN AG has never served as project coordinator in the H2020 data, always joining as a partner or third party — a pattern consistent with a specialist company that brings proprietary technology and screening capacity to consortia rather than administrative leadership. Their network of 30 partners across 11 countries from just two projects suggests they plug into large, multi-partner consortia where their enzyme engineering expertise is one of several complementary capabilities. This makes them a reliable specialist contributor: they deliver defined technical workpackages and are experienced navigating complex consortium dynamics without needing to drive the project.

Despite only two H2020 projects, BRAIN AG has accumulated 30 unique consortium partners across 11 countries — indicating participation in genuinely large international consortia rather than small bilateral collaborations. Their geographic spread is pan-European with no apparent regional concentration.

What sets them apart

BRAIN AG occupies a rare position as a non-SME private industrial biotech company in EU research consortia — they bring commercial-grade enzyme engineering capability that most academic partners cannot match, while remaining small enough to operate with agility. Unlike university labs, their protein and enzyme work is calibrated toward real product pipelines: scalability, cost-of-goods, and regulatory readiness are built into how they approach problems. For a consortium building a project that needs to demonstrate industrial relevance or TRL advancement in biotechnology, BRAIN AG provides credibility that bridges bench science and the market.

Highlights from their portfolio

• RADICALZ
  The flagship project in this dataset — EUR 527,450 in EC funding — combines five advanced technologies (microfluidics, metagenomics, protein engineering, ML, bioprocess sustainability) in a single applied programme targeting greener consumer products, making it BRAIN AG's most technically comprehensive and commercially-oriented EU engagement.
• ES-Cat
  An MSCA Innovative Training Network focused on directed protein evolution for synthetic biology, this project shows BRAIN AG's role in training the next generation of European enzyme engineers — a signal of deep scientific credibility beyond commercial product work.